-transparent.png){kind=logo}
CN 3123 was tested in 4 hospitals on 257 children, 218 of whom were included in the evaluation of the success of therapy. It was administered for the treatment of urinary tract infections (n = 125), bronchial infections (n = 24), intestinal infections (n = 25) and ENT infections (n = 37). The results indicated that, with a failure rate of only 7%, the drug was successfully employed. Tolerance to the medicament was good. Vomiting occurred in 7 children (2.7%) and allergic skin reactions were observed in 6 children (2.3%). A comparative study of CN 3123 and Co-trimoxazole showed the same efficacy and tolerance for both medicaments.
Related Publications
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1976,
Arzneimittel-Forschung,
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1976,
Arzneimittel-Forschung,
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1976,
Arzneimittel-Forschung,
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1976,
Arzneimittel-Forschung,
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1976,
Arzneimittel-Forschung,
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1976,
Arzneimittel-Forschung,
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1976,
Arzneimittel-Forschung,
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1976,
Arzneimittel-Forschung,
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1981,
Indian journal of dermatology, venereology and leprology,
H Helwig, and
M Bulla, and
W Sitzmann, and
K Schreier, and
K Loh, and
A Wodetzky
January 1976,
Arzneimittel-Forschung,
